Advertisement

Related Videos

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Advertisement

Advertisement




May
03
Today In Oncology
FDA Approves Vepdegestrant for ER-HER2 ESR1 Advanced Breast Cancer
Melanoma Gut Microbiome May Help Predict Recurrence After Immunotherapy
Association of Body Size and Bladder Cancer Risk
5-Year Follow-Up From AUGMENT Lenalidomide Plus Rituximab in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
Can PFAS Exposure Raise ALL Risk?
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo